clinical trial · NCT07542314
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
Duchenne Muscular DystrophyELEVIDYSSirolimusGlucocorticoidsAntibiotics
brief summary
The primary objective of this study is to evaluate acute liver injury (ALI) rates associated with ELEVIDYS with the addition of sirolimus as an adjunct prophylactic immunosuppression agent.
started
Apr 30, 2026
primary completion
Mar 31, 2027
completion
Mar 31, 2027
last updated
Apr 21, 2026
official title
Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (ENHANCE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol